

Chronic myeloid leukemia and the use of tyrosine kinase inhibitors in the days of COVID-19 pandemic

Ahmet Emre Eşkazan¹

¹Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine

April 28, 2020

Abstract

Tyrosine kinase inhibitors (TKIs) have revolutionized the management of chronic myeloid leukemia (CML), and currently in patients with CML in chronic phase (CML-CP) the first-line treatment is based on *BCR-ABL* targeted therapy with TKIs [1]. Although generally well tolerated, all *BCR-ABL* TKIs can be associated with hematologic and non-hematologic toxicities [2]. Most of the patients with CML-CP continue receiving TKIs, unless there is lack of optimal response and/or serious toxicities.

Hosted file

BJCP Editorial.doc available at <https://authorea.com/users/310728/articles/441514-chronic-myeloid-leukemia-and-the-use-of-tyrosine-kinase-inhibitors-in-the-days-of-covid-19-pandemic>